ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sana Biotechnology, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on May 20, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Sana securities between March 17, 2023, and November 4, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 20, 2025 [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Allegations Against Sana Biotechnology - The lawsuit alleges that during the Class Period, Sana made false or misleading statements regarding its financial stability and the potential of its product candidates [4]. - Specific claims include that Sana was at significant risk of insufficient funds, that certain product candidates were less promising than represented, and that the company was likely to decrease funding for some projects and reduce its workforce [4].